DUSEK, Jaroslav, Zuzana MOTOVSKA, Ota HLINOMAZ, Roman MIKLÍK, Milan HROMADKA, Ivo VARVAROVSKY, Jiří JARKOVSKÝ, Frantisek TOUSEK, Bohumil MAJTAN, Stanislav SIMEK, Marian BRANNY, Jan MROZEK and Petr WIDIMSKY. The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudy. International Journal of Cardiology. Clare: Elsevier Ireland Ltd., 2020, vol. 319, NOV 2020, p. 1-6. ISSN 0167-5273. Available from: https://dx.doi.org/10.1016/j.ijcard.2020.06.067.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudy
Authors DUSEK, Jaroslav (203 Czech Republic), Zuzana MOTOVSKA (203 Czech Republic, guarantor), Ota HLINOMAZ (203 Czech Republic, belonging to the institution), Roman MIKLÍK (203 Czech Republic, belonging to the institution), Milan HROMADKA (203 Czech Republic), Ivo VARVAROVSKY (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Frantisek TOUSEK (203 Czech Republic), Bohumil MAJTAN (203 Czech Republic), Stanislav SIMEK (203 Czech Republic), Marian BRANNY (203 Czech Republic), Jan MROZEK (203 Czech Republic) and Petr WIDIMSKY (203 Czech Republic).
Edition International Journal of Cardiology, Clare, Elsevier Ireland Ltd. 2020, 0167-5273.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.164
RIV identification code RIV/00216224:14110/20:00116817
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.ijcard.2020.06.067
UT WoS 000580586000001
Keywords in English Acute myocardial infarction; Primary percutaneous coronary intervention; Periprocedural myocardial infarction; Prognosis
Tags 14110115, 14110211, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 24/7/2023 12:59.
Abstract
Background: The prognostic significance of periprocedural myocardial infarction (MI) remains controversial. Methods and results: The study aims to investigate the incidence of periprocedural MI in the era of high sensitivity diagnostic markers and intense antithrombotics, and its impact on early outcomes of patients with acute MI treated with primary angioplasty (pPCI). Data from the PRAGUE-18 (prasugrel versus ticagrelor in pPCI) study were analyzed. The primary net-clinical endpoint (EP) included death, spontaneous MI, stroke, severe bleeding, and revascularization at day 7. The key secondary efficacy EP included cardiovascular death, spontaneous MI, and stroke within 30 days. The incidence of peri-pPCI MI was 2.3% (N = 28) in 1230 study patients. The net-clinical EP occurred in 10.7% of patients with, and in 3.6% of patients without, peri-pPCI MI (HR 2.92; 95% CI 0.91-9.38; P = 0.059). The key efficacy EP was 10.7% and 3.2%, respectively (HR 3.44; 95% CI 1.06-11.13; P = 0.028). Patients with periprocedural MI were at a higher risk of spontaneous MI (HR 6.19; 95% CI 1.41-27.24; P = 0.006) and stent thrombosis (HR 10.77; 95% CI 2.29-50.70; P = 0.003) within 30 days. Age, hyperlipidemia, multi-vessel disease, post-procedural TIMI <3, pPCI on circumflex coronary artery, and periprocedural GP IIb/IIIa inhibitor were independent predictors of peri-pPCI MI. Conclusions: In the era of intense antithrombotic therapy, the occurrence of peri-pPCI MI is despite highly sensitive diagnostic markers a rare complication, and is associated with an increased risk of early reinfarction and stent thrombosis. (C) 2020 Elsevier B.V. All rights reserved.
Links
LM2018128, research and development projectName: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 12/5/2024 05:01